BUSINESS
Indian pharma market continues to cool down in July on lag in acute therapies
A slow offtake in the acute season resulted in weaker sales within the segment, dragging overall sales growth in the domestic pharma market in July.
BUSINESS
Mid-day Mood | Market cracks under pressure, most sectors trade in the red
The RBI's surprise spike in inflation forecasts continued to drag sentiment and also offset the lower-than-expected US CPI print for July.
BUSINESS
Analysts take contrarian calls even as investors swoon over Sun Pharma
As per Moneycontrol's Analyst Call Tracker, the stock topped the list of contrarian calls taken by brokerages, with ‘hold’ ratings going from zero to three in July even as the scrip gained in the cash market
BUSINESS
Mid-day Mood | Nifty slips below 19,500, Sensex sheds over 370 points on weak global cues
Benchmark indices in the US ended lower on Tuesday after Moody's downgraded a few regional US banks, sending out negative cues to global markets.
BUSINESS
Mid-day Mood | Market listless ahead of RBI policy, US inflation data
Market participants are awaiting the RBI's rate outcome and the US retail inflation print for July, which will be released on August 10. Stocks were also reacting to June quarter numbers
BUSINESS
Mid-day Mood | Rally in pharma stocks keeps indices in green; FMCG drags
The broader market also moved in tandum with the headline indices, with the Nifty Midcap 100 and Nifty Smallcap 100 trading marginally higher.
BUSINESS
Changing dynamics: What’s fuelling growth in the US generics market?
Large-cap pharma players Dr Reddy’s, Cipla, Lupin and Sun Pharma all reported strong growth in the US market in the April-June quarter, with the generics segment faring better than Street expectations. We take a deep dive into the reasons for this turnaround.
BUSINESS
Brokerages positive on Sun Pharma's growth but investors unimpressed
Sun Pharma incurred an exceptional loss worth Rs 322.87 crore in Q1, which dragged its net profit lower. Excluding that, the company's bottomline was well above analyst expectations
BUSINESS
Concord Biotech IPO opens: Can this Big Bull-backed pharma player create magic?
Subscribing to the IPO may suit investors looking for a long-term investment but those looking for blockbuster returns like Mankind Pharma should probably temper their expectations. Read on to find out why
BUSINESS
Sun Pharma Q1 preview: Subdued growth on weak Taro numbers, muted US sales
Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.
BUSINESS
Lupin Q1 Preview: Healthy US sales, favourable base to lift earnings
Easing headwinds which dragged Lupin's financials in the base quarter, along with healthy sales in the US are likely to lift financials for the drugmaker in Q1.
BUSINESS
Fitch Fallout: Nifty closes above 19,500 thanks to late buying, Sensex falls 677 points
Indian equity markets are mirroring a trend that is playing out across the Asian and European regions, with the Nifty falling about a percent.
BUSINESS
Nifty in August company as rollover hints at further gains
The index is seeing the fourth straight month of gains in the F&O series as it enters August. Brokerages expect the Nifty to hit fresh all-time highs, given the overall derivatives activity. In the last 26 years, the index has closed 59% in the green in the month of August.
BUSINESS
UPL Preview: Tepid demand, high-cost inventory destocking to weigh on Q1 earnings
Brokerages have painted bleak Q1 numbers for UPL as profit, revenue as well as operating margins are expected to decline year-on-year.
BUSINESS
Brokerages roll out a cautious growth outlook for IEX; shares flat
In recent times, the company's shares have been facing persistent downward pressure, primarily due to the Central Electricity Regulatory Commission's intention to introduce market coupling.
BUSINESS
Will Cipla shares scale greater heights if PE players buy stakes?
There are reports that PE firms Blackstone and Baring Asia, among others, are in talks with Cipla for buying stakes in the company. If the deal goes through, analysts say it will present a greater expanse for growth for one of India's leading drug makers
BUSINESS
Dr Reddy’s Q1: Just an overdose of Revlimid, not much growth ahead, say brokerages
Even though the company’s profit, revenue and profitability exceeded expectations, brokerages feel that the growth in recent quarters was fueled by the spectacular sales of Revlimid. They say the contribution from the drug will soon start waning out, and many still retain their ‘hold’ and ‘sell’ calls.
BUSINESS
Market washes away recent gains as profit booking kicks in: Key factors behind fall
Despite the profit booking, analysts maintain their positive outlook on the market and see the consolidation as healthy breather.
BUSINESS
Cipla zooms 9% on stronger-than-expected Q1; brokerages cheer, raise targets
Cipla's management also guided for a strong growth outlook across segments for the upcoming quarters, which lifted sentiment for the drugmaker.
BUSINESS
Fed staff drops US recession forecasts, what it means for Indian markets?
The US central bank's staff has clawed back its expectations of a 'mild recession' later in the year, as they no longer forecast a recession in the world's largest economy
BUSINESS
Cipla raises margin guidance for FY24 to 23% on strong Q1
"A good quarter gone by gives us the confidence to raise margin guidance," said Umang Vohra, chief executive officer, Cipla.
BUSINESS
Mid-day Mood: Market rebounds as heavyweights join the party
All sectors traded in the green, while several heavyweights also helped in lifting the market higher.
BUSINESS
Cipla Q1 Preview: Steady earnings expected, strong India growth to offset subdued US sales
Most brokerages see Cipla as the frontrunner of growth within the domestic market in Q1 which will help offset the adverse impact of a moderation in US sales.
BUSINESS
Dr Reddy's Q1 Preview: Strong US sales, drug launches to drive strong growth
Continued boost from sales of the blockbuster drug Revlimid along with launches of a few inhalation drug is expected to fuel a jump in US sales for Dr Reddy's.
